VivoSeq
Cardiovascular

Congestive Heart Failure

103

Pipeline Programs↗

5

Active Trials↗

45

Companies Involved↗

Congestive Heart Failure is a highly competitive landscape with 103 programs across 45 companies. The most active players are Stealth BioTherapeutics Inc., Sarfez Pharmaceuticals, Inc., Daiichi Sankyo. 42 therapies are approved with 19 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

15/100

Mech. Concentration

7/100

Completion Rate

69/100

Attrition Rate

26/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Stealth BioTherapeutics Inc.

1 program

Phase 1S

Sarfez Pharmaceuticals, Inc.

1 program

Phase 2Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 2T

Titan Pharmaceuticals

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2Novo Nordisk logo

Novo Nordisk

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical16

Levosimendan

Orion Corporation, Orion Pharma

Alteplase

Roche

Sodium Nitroprusside

Watson Pharmaceuticals

Metoprolol Succinate

AstraZeneca

Atorvastatin Calcium

Merck & Co.

Phase 14

MTP-131

Stealth BioTherapeutics Inc.

NG-Monomethyl-L-Arginine

Medical University of Vienna

Nesiritide, Sildenafil

Mayo Clinic

Low Dose Aspirin

Mayo Clinic

Phase 222

Albiglutide

GSK

Torsemide

Sarfez Pharmaceuticals, Inc.

Prednisone

Roxane Laboratories

Amiodarone

Wyeth-Lederle Vaccines

Empagliflozin

Boehringer Ingelheim

Phase 319

Candesartan

AstraZeneca

Nesiritide

Scios, Inc.

Ferrous Sulfate

Auerbach Hematology Oncology Associates P C

Pantoprazole

Wyeth-Lederle Vaccines

Dronedarone

Sanofi

Approved42

Thalidomide

Bristol-Myers Squibb

Furosemide

Validus Pharmaceuticals

Ivabradine

Amgen

Hydrochlorothiazide

AbbVie

Eplerenone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Analysis

Modality Breakdown

94%

Small molecule

101 of 108 classified programs — the dominant modality here.

6%ALL OTHERSPeptide55%Protein / enzyme1<1%Vaccine1<1%

Small molecule leads; the ring shows all 108 classified programs, each share of the total. Modality classified for 100% of 114 pipeline programs.

Analysis

Trial Status

94

clinical trials

Completed56 · 60%
Terminated17 · 18%
Unknown status8 · 9%
Withdrawn7 · 7%
Not yet recruiting3 · 3%
Recruiting1 · 1%
Other2 · 2%

Clinical Trials

Trial Activity

94 trials

Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate.
Recruiting·—·Phase 2·NCT06705023·36 enrolled
Evaluation of the Multisite Replication of the Transitional Care Model
Active, not recruiting·MMathematica Policy Research, Inc.·Preclinical·NCT04212962·962 enrolled
Reducing the Length of Stay and Incidence of Rehospitalization in Heart Failure Patients by Measuring Peripheral Venous Pressure; a Randomized Clinical Trial
Not yet recruiting·WWake Forest University Health Sciences·Preclinical·NCT07400042·600 enrolled
Health Coaching for Patients With Cardiovascular Disease: A Mixed-Methods Evaluation of the Impact on Patient Outcomes and Provider Satisfaction and Acceptability
Not yet recruiting·OOhio State University·Preclinical·NCT06904144·70 enrolled
Boston Medical Center Ultrasound Decongestion Study
Not yet recruiting·BBoston Medical Center·Preclinical·NCT07096726·200 enrolled
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00159627·52 enrolled
Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure
Completed·Otsuka logoOtsuka·Phase 2·NCT00132886·140 enrolled
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT00259038·162 enrolled
Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder
Completed·SSarfez Pharmaceuticals, Inc.·Phase 2·NCT06206512·24 enrolled
Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
Completed·Otsuka logoOtsuka·Phase 3·NCT03772041·294 enrolled
Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake
Completed·Otsuka logoOtsuka·Phase 3·NCT03962101·45 enrolled
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
Completed·Institut de Recherches Internationales Servier logoInstitut de Recherches Internationales Servier·Phase 2·NCT00202579·12 enrolled
Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure
Completed·CCardioKine Inc.·Phase 2·NCT01055912·170 enrolled
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
Completed·—·Phase 3·NCT00023595·2,136 enrolled
The Use of Intranasal Fentanyl for the Treatment of Incident Dyspnea in Congestive Heart Failure: A Prospective Trial
Completed·—·Phase 2·NCT02454751·8 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)